Study S002125

Efficacy and Safety of Cagrilintide s.c. 2.4 mg in Combination With Semaglutide s.c. 2.4 mg (CagriSema s.c. 2.4 mg/2.4 mg) Once-Weekly in Chinese Participants With Overweight or Obesity

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT05996848
Acronym: REDEFINE 6
Study type: INTERVENTIONAL
Allocation: RANDOMIZED
Phase: PHASE3
Masking: DOUBLE
Status: COMPLETED
Enrollment: 300
Start: 2023-08-15
Primary completion: 2025-01-06
Lead sponsor: Novo Nordisk A/S
Conditions: Obesity or Overweight
Interventions: DRUG:Cagrilintide; DRUG:Semaglutide; DRUG:Placebo Semaglutide; DRUG:Placebo Cagrilintide
Results posted: FALSE
Individual participant data sharing: YES
Secondary identifiers: OTHER:U1111-1267-4364

Registered primary outcomes

CagriSema 2.4 mg/2.4 mg versus placebo: Relative change in body weight [From baseline (week 0) to end of treatment (week 44)]
CagriSema 2.4 mg/2.4 mg versus placebo: Number of participants who achieve (yes/no): Body weight reduction greater than or equal to 5% [From baseline (week 0) to end of treatment (week 44)]

Linked records (0)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

No records link to this registration yet.